Reflecting enthusiasm for a radiotherapy that can target multiple tumors simultaneously, Reflexion Medical Inc. closed an $80 million series E fundraising round to support development of its biology-guided radiotherapy (BgRT) technology for metastatic cancer. New investors included Ascension Ventures, Catalio Capital Management LP, Sixty Degree Capital Inc. and Hillenbrand Capital Partners LLC.
Investors are backing precision medicine company Cancer IQ Inc. with $14 million to expand use of its cancer prevention platform. The series B funds will be used to scale the company’s cancer screening service among diverse, uninsured, and rural populations in the U.S.
Egg Medical Inc. secured a $13 million investment from TVM Capital Life Science to solve the Humpty-Dumpty problem that plagues interventional cardiology – the scattering of radiation during X-ray guided procedures. The company’s Eggnest XR product contains the radiation using a carbon fiber platform with integrated radiation shielding that replaces the patient mattress on the X-ray table.
Chinese company Seekin Inc. is preparing to launch its cancer detection technology in Europe after securing CE marking for the Seekincare pan-cancer test. The artificial intelligence, blood-based platform uses insights from public and private data to identify cancer DNA and protein signals in the blood. The test has been available in Chinese labs since 2018.
Oxford Biodynamics plc is launching its clinical assay Episwitch CIRT in the U.S. following clinical validation that demonstrated the 3D genomic eight biomarker panel can predict a cancer patient’s response to immune checkpoint inhibitor (ICI) therapy at up to 93% sensitivity, 82% specificity and 85% accuracy. ICIs are currently used against more than 15 types of cancer but less than one in three patients show any benefit from the treatment.
PARIS – Siemens Healthineers AG has unveiled its growth plans for 2025 at its annual general meeting. The Erlangen, Germany-based medical technology giant, valued at nearly $67 billion on the Frankfurt stock exchange, is ramping growth. “We are setting ourselves the objective of annual growth of up to 8% on a like-for-like basis up to 2025, compared with a previous objective of 5%,” said Ralf Thomas, supervisory board chairman, Siemens Healthineers AG. Adjusted earnings per share should, accordingly, rise by 15% a year over that period as part of this strategic plan, compared with a target of at least 10% previously.
The U.S. CMS has expanded the population of Medicare beneficiaries who are eligible for lung cancer screening via low-dose CT (LDCT) imaging. The news drew raves from stakeholders who also lauded the expansion of the facilities that can conduct the procedure, constituting a set of changes that advocates say will save thousands of additional lives.
The U.S. FDA has granted Datar Cancer Genetics Ltd. a breakthrough device designation for a blood test to detect early-stage prostate cancer. The circulating tumor cell (CTC) detection blood test can identify early-stage prostate cancer in men of age 55-69 years at around 99% accuracy.
PERTH, Australia – Impedimed Ltd.’s L-Dex bioimpedance technology could quickly become the standard of care for measuring cancer-related lymphedema following clinical trial results that showed a 59% relative reduction in progression compared to the standard of care, Impedimed CEO Rick Carreon told BioWorld.
Blue Note Therapeutics Inc. took a new approach to expanding its pipeline of prescription digital therapeutics (PDT) with an exclusive licensing agreement with the University of Sydney for Conquerfear, a metacognitive intervention that helps cancer survivors cope with the fear of disease recurrence. Blue Note has developed its PDTs internally to date but hopes to convert Conquerfear’s elements, which are typically delivered face-to-face, into a PDT for the U.S. and Canada. As a digital therapy, the program could potentially reach many more patients.